SB 203580 (152121-47-6) is a potent and selective inhibitor of p38 MAP kinase, IC50=50 and 500 nM for p38 and p38β2 respectively. No other kinases (in a panel of 30) were significantly inhibited including p38γ and δ at 10 μM2. A potent inhibitor of inflammatory cytokine production (IC50=15-25 mg/kg in mice and rats) in animal models of arthritis, bone resorption, endotoxin shock and immune function3.
1) Cuenda et al. (1995), SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1; FEBS Lett., 364 229
2) Davies et al. (2000), Specificity and mechansim of action of some commonly used protein kinase inhibitors; Biochem. J., 351 95
3) Badger et al. (1996), Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function; Pharmacol. Exp. Ther. 279 1453